Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Feb 16, 2023 3:12pm
72 Views
Post# 35290544

RE:RE:Interesting committee they've formed

RE:RE:Interesting committee they've formedI wouldn't disagree with your conclusion. But when an effort is completely dependent on experimentation into the unknown, the value of someone who's traveled that path a few hundred times more than you have and has a far more developed knowledgebase about data hypothesis, comparative/similar approaches and what-ifs, that can be really valuable. If they signed on to help understand the key issues, they should have the tools to get from data observation to theory to hypothsis to revised protocal (if they get there) pretty quickly. I guess one way to think about it is that new sets of highly experienced eyes can't hurt. May not help, but can't hurt given where they are. The possibiliity is there to conclude all the outcomes mentioned here from best to worst. But worst is already the assumption in the market.
<< Previous
Bullboard Posts
Next >>